Vanguard Group Inc Brainstorm Cell Therapeutics Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,400,993 shares of BCLI stock, worth $602,426. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,400,993
Previous 1,423,310
1.57%
Holding current value
$602,426
Previous $384,000
104.17%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding BCLI
# of Institutions
52Shares Held
4.09MCall Options Held
63.2KPut Options Held
800-
Black Rock Inc. New York, NY489KShares$210,4040.0% of portfolio
-
Geode Capital Management, LLC Boston, MA357KShares$153,5270.0% of portfolio
-
Liberty Wealth Management LLC Oakland, CA340KShares$146,2640.04% of portfolio
-
Weaver Consulting Group199KShares$85,7230.04% of portfolio
-
Caldwell Sutter Capital, Inc. Sausalito, CA157KShares$67,5130.0% of portfolio
About BRAINSTORM CELL THERAPEUTICS INC.
- Ticker BCLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,486,200
- Market Cap $15.7M
- Description
- Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...